0
     

La Merie Business Intelligence

La Merie Business Intelligence

Total Post Count: 8 of 8


Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective